Publications

Publications published since 2002 from OUS - Epigenetics (Lind)

51 publications found

Publications 2024

  1. Langerud J, Eilertsen IA, Moosavi SH, Klokkerud SMK, Reims HM, Backe IF, Hektoen M, Sjo OH, Jeanmougin M, Tejpar S, Nesbakken A, Lothe RA, Sveen A (2024)
    Multiregional transcriptomics identifies congruent consensus subtypes with prognostic value beyond tumor heterogeneity of colorectal cancer
    Nat Commun, 15 (1), 4342
    DOI 10.1038/s41467-024-48706-2, PubMed 38773143
  2. Vedeld HM, Pharo H, Sørbø AK, Brandt-Winge S, Five MB, Jeanmougin M, Guldberg P, Wahlqvist R, Lind GE (2024)
    Distinct longitudinal patterns of urine tumor DNA in patients undergoing surveillance for bladder cancer
    Mol Oncol, 18 (11), 2684-2695
    DOI 10.1002/1878-0261.13639, PubMed 38720532

Publications 2023

  1. Jeanmougin M, Brodal HP, Dietrichson Pharo H, Vedeld HM, Lind GE (2023)
    PoDCall: positive droplet calling and normalization of droplet digital PCR DNA methylation data
    Bioinformatics, 39 (1)
    DOI 10.1093/bioinformatics/btac766, PubMed 36448696
  2. Kresse SH, Brandt-Winge S, Pharo H, Flatin BTB, Jeanmougin M, Vedeld HM, Lind GE (2023)
    Evaluation of commercial kits for isolation and bisulfite conversion of circulating cell-free tumor DNA from blood
    Clin Epigenetics, 15 (1), 151
    DOI 10.1186/s13148-023-01563-0, PubMed 37710283

Publications 2022

  1. Bergsland CH, Jeanmougin M, Moosavi SH, Svindland A, Bruun J, Nesbakken A, Sveen A, Lothe RA (2022)
    Spatial analysis and CD25-expression identify regulatory T cells as predictors of a poor prognosis in colorectal cancer
    Mod Pathol, 35 (9), 1236-1246
    DOI 10.1038/s41379-022-01086-8, PubMed 35484226
  2. Namløs HM, Skårn M, Ahmed D, Grad I, Andresen K, Kresse SH, Munthe E, Serra M, Scotlandi K, Llombart-Bosch A, Myklebost O, Lind GE, Meza-Zepeda LA (2022)
    miR-486-5p expression is regulated by DNA methylation in osteosarcoma
    BMC Genomics, 23 (1), 142
    DOI 10.1186/s12864-022-08346-6, PubMed 35172717
  3. Pharo HD, Jeanmougin M, Ager-Wick E, Vedeld HM, Sørbø AK, Dahl C, Larsen LK, Honne H, Brandt-Winge S, Five MB, Monteiro-Reis S, Henrique R, Jeronimo C, Steven K, Wahlqvist R, Guldberg P, Lind GE (2022)
    BladMetrix: a novel urine DNA methylation test with high accuracy for detection of bladder cancer in hematuria patients
    Clin Epigenetics, 14 (1), 115
    DOI 10.1186/s13148-022-01335-2, PubMed 36115961
  4. Pinto R, Hauge T, Jeanmougin M, Pharo HD, Kresse SH, Honne H, Winge SB, Five MB, Kumar T, Mala T, Hauge T, Johnson E, Lind GE (2022)
    Targeted genetic and epigenetic profiling of esophageal adenocarcinomas and non-dysplastic Barrett's esophagus
    Clin Epigenetics, 14 (1), 77
    DOI 10.1186/s13148-022-01287-7, PubMed 35701814

Publications 2021

  1. Davydova E, Shimazu T, Schuhmacher MK, Jakobsson ME, Willemen HLDM, Liu T, Moen A, Ho AYY, Małecki J, Schroer L, Pinto R, Suzuki T, Grønsberg IA, Sohtome Y, Akakabe M, Weirich S, Kikuchi M, Olsen JV, Dohmae N, Umehara T, Sodeoka M, Siino V, McDonough MA, Eijkelkamp N, Schofield CJ et al. (2021)
    The methyltransferase METTL9 mediates pervasive 1-methylhistidine modification in mammalian proteomes
    Nat Commun, 12 (1), 891
    DOI 10.1038/s41467-020-20670-7, PubMed 33563959
  2. Vedeld HM, Grimsrud MM, Andresen K, Pharo HD, von Seth E, Karlsen TH, Honne H, Paulsen V, Färkkilä MA, Bergquist A, Jeanmougin M, Aabakken L, Boberg KM, Folseraas T, Lind GE (2021)
    Early and accurate detection of cholangiocarcinoma in patients with primary sclerosing cholangitis by methylation markers in bile
    Hepatology, 75 (1), 59-73
    DOI 10.1002/hep.32125, PubMed 34435693

Publications 2020

  1. Flatin BTB, Vedeld HM, Pinto R, Langerud J, Lind GE, Lothe RA, Sveen A, Jeanmougin M (2020)
    Multiregional assessment of CIMP in primary colorectal cancers: Phenotype concordance but marker variability
    Int J Cancer, 148 (7), 1652-1657
    DOI 10.1002/ijc.33425, PubMed 33284993
  2. Jeanmougin M, Håvik AB, Cekaite L, Brandal P, Sveen A, Meling TR, Ågesen TH, Scheie D, Heim S, Lothe RA, Lind GE (2020)
    Improved prognostication of glioblastoma beyond molecular subtyping by transcriptional profiling of the tumor microenvironment
    Mol Oncol, 14 (5), 1016-1027
    DOI 10.1002/1878-0261.12668, PubMed 32171051
  3. Lopes N, Bergsland C, Bruun J, Bjørnslett M, Vieira AF, Mesquita P, Pinto R, Gomes R, Cavadas B, Bennett E, Pereira L, Lothe RA, Almeida R, David L (2020)
    A panel of intestinal differentiation markers (CDX2, GPA33, and LI-cadherin) identifies gastric cancer patients with favourable prognosis
    Gastric Cancer, 23 (5), 811-823
    DOI 10.1007/s10120-020-01064-6, PubMed 32215766
  4. Vedeld HM, Folseraas T, Lind GE (2020)
    Detecting cholangiocarcinoma in patients with primary sclerosing cholangitis - The promise of DNA methylation and molecular biomarkers
    JHEP Rep, 2 (5), 100143
    DOI 10.1016/j.jhepr.2020.100143, PubMed 32939446

Publications 2019

  1. Larsen LK, Lind GE, Guldberg P, Dahl C (2019)
    DNA-Methylation-Based Detection of Urological Cancer in Urine: Overview of Biomarkers and Considerations on Biomarker Design, Source of DNA, and Detection Technologies
    Int J Mol Sci, 20 (11)
    DOI 10.3390/ijms20112657, PubMed 31151158
  2. Marcuello M, Vymetalkova V, Neves RPL, Duran-Sanchon S, Vedeld HM, Tham E, van Dalum G, Flügen G, Garcia-Barberan V, Fijneman RJ, Castells A, Vodicka P, Lind GE, Stoecklein NH, Heitzer E, Gironella M (2019)
    Circulating biomarkers for early detection and clinical management of colorectal cancer
    Mol Aspects Med, 69, 107-122
    DOI 10.1016/j.mam.2019.06.002, PubMed 31189073

Publications 2018

  1. Pharo HD, Andresen K, Berg KCG, Lothe RA, Jeanmougin M, Lind GE (2018)
    A robust internal control for high-precision DNA methylation analyses by droplet digital PCR
    Clin Epigenetics, 10, 24
    DOI 10.1186/s13148-018-0456-5, PubMed 29484034
  2. Pinto D, Pinto C, Guerra J, Pinheiro M, Santos R, Vedeld HM, Yohannes Z, Peixoto A, Santos C, Pinto P, Lopes P, Lothe R, Lind GE, Henrique R, Teixeira MR (2018)
    Contribution of MLH1 constitutional methylation for Lynch syndrome diagnosis in patients with tumor MLH1 downregulation
    Cancer Med, 7 (2), 433-444
    DOI 10.1002/cam4.1285, PubMed 29341452
  3. Vedeld HM, Nesbakken A, Lothe RA, Lind GE (2018)
    Re-assessing ZNF331 as a DNA methylation biomarker for colorectal cancer
    Clin Epigenetics, 10, 70
    DOI 10.1186/s13148-018-0503-2, PubMed 29854011

Publications 2017

  1. Berg KCG, Eide PW, Eilertsen IA, Johannessen B, Bruun J, Danielsen SA, Bjørnslett M, Meza-Zepeda LA, Eknæs M, Lind GE, Myklebost O, Skotheim RI, Sveen A, Lothe RA (2017)
    Multi-omics of 34 colorectal cancer cell lines - a resource for biomedical studies
    Mol Cancer, 16 (1), 116
    DOI 10.1186/s12943-017-0691-y, PubMed 28683746
  2. Lind GE, Guriby M, Ahlquist T, Hussain I, Jeanmougin M, Søreide K, Kørner H, Lothe RA, Nordgård O (2017)
    Prognostic relevance of an epigenetic biomarker panel in sentinel lymph nodes from colon cancer patients
    Clin Epigenetics, 9, 97
    DOI 10.1186/s13148-017-0397-4, PubMed 28878843
  3. Lind GE, van Engeland M (2017)
    Details matter: the role of genomic location and assay standardization in DNA methylation analyses
    Epigenomics, 9 (7), 933-935
    DOI 10.2217/epi-2017-0053, PubMed 28617096
  4. Sveen A, Johannessen B, Tengs T, Danielsen SA, Eilertsen IA, Lind GE, Berg KCG, Leithe E, Meza-Zepeda LA, Domingo E, Myklebost O, Kerr D, Tomlinson I, Nesbakken A, Skotheim RI, Lothe RA (2017)
    Multilevel genomics of colorectal cancers with microsatellite instability-clinical impact of JAK1 mutations and consensus molecular subtype 1
    Genome Med, 9 (1), 46
    DOI 10.1186/s13073-017-0434-0, PubMed 28539123
  5. Vedeld HM, Goel A, Lind GE (2017)
    Epigenetic biomarkers in gastrointestinal cancers: The current state and clinical perspectives
    Semin Cancer Biol, 51, 36-49
    DOI 10.1016/j.semcancer.2017.12.004, PubMed 29253542
  6. Vedeld HM, Merok M, Jeanmougin M, Danielsen SA, Honne H, Presthus GK, Svindland A, Sjo OH, Hektoen M, Eknaes M, Nesbakken A, Lothe RA, Lind GE (2017)
    CpG island methylator phenotype identifies high risk patients among microsatellite stable BRAF mutated colorectal cancers
    Int J Cancer, 141 (5), 967-976
    DOI 10.1002/ijc.30796, PubMed 28542846

Publications 2016

  1. Banales JM, Cardinale V, Carpino G, Marzioni M, Andersen JB, Invernizzi P, Lind GE, Folseraas T, Forbes SJ, Fouassier L, Geier A, Calvisi DF, Mertens JC, Trauner M, Benedetti A, Maroni L, Vaquero J, Macias RI, Raggi C, Perugorria MJ, Gaudio E, Boberg KM, Marin JJ, Alvaro D (2016)
    Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)
    Nat Rev Gastroenterol Hepatol, 13 (5), 261-80
    DOI 10.1038/nrgastro.2016.51, PubMed 27095655
  2. Cekaite L, Eide PW, Lind GE, Skotheim RI, Lothe RA (2016)
    MicroRNAs as growth regulators, their function and biomarker status in colorectal cancer
    Oncotarget, 7 (6), 6476-505
    DOI 10.18632/oncotarget.6390, PubMed 26623728
  3. Pharo HD, Honne H, Vedeld HM, Dahl C, Andresen K, Liestøl K, Jeanmougin M, Guldberg P, Lind GE (2016)
    Experimental factors affecting the robustness of DNA methylation analysis
    Sci Rep, 6, 33936
    DOI 10.1038/srep33936, PubMed 27671843

Publications 2015

  1. Andresen K, Boberg KM, Vedeld HM, Honne H, Jebsen P, Hektoen M, Wadsworth CA, Clausen OP, Lundin KE, Paulsen V, Foss A, Mathisen Ø, Aabakken L, Schrumpf E, Lothe RA, Lind GE (2015)
    Four DNA methylation biomarkers in biliary brush samples accurately identify the presence of cholangiocarcinoma
    Hepatology, 61 (5), 1651-9
    DOI 10.1002/hep.27707, PubMed 25644509
  2. Bruun J, Kolberg M, Ahlquist TC, Røyrvik EC, Nome T, Leithe E, Lind GE, Merok MA, Rognum TO, Bjørkøy G, Johansen T, Lindblom A, Sun XF, Svindland A, Liestøl K, Nesbakken A, Skotheim RI, Lothe RA (2015)
    Regulator of Chromosome Condensation 2 Identifies High-Risk Patients within Both Major Phenotypes of Colorectal Cancer
    Clin Cancer Res, 21 (16), 3759-70
    DOI 10.1158/1078-0432.CCR-14-3294, PubMed 25910952
  3. Kolberg M, Høland M, Lind GE, Ågesen TH, Skotheim RI, Hall KS, Mandahl N, Smeland S, Mertens F, Davidson B, Lothe RA (2015)
    Protein expression of BIRC5, TK1, and TOP2A in malignant peripheral nerve sheath tumours--A prognostic test after surgical resection
    Mol Oncol, 9 (6), 1129-39
    DOI 10.1016/j.molonc.2015.02.005, PubMed 25769404

Publications 2014

  1. Almeida M, Costa VL, Costa NR, Ramalho-Carvalho J, Baptista T, Ribeiro FR, Paulo P, Teixeira MR, Oliveira J, Lothe RA, Lind GE, Henrique R, Jerónimo C (2014)
    Epigenetic regulation of EFEMP1 in prostate cancer: biological relevance and clinical potential
    J Cell Mol Med, 18 (11), 2287-97
    DOI 10.1111/jcmm.12394, PubMed 25211630
  2. Bethge N, Honne H, Andresen K, Hilden V, Trøen G, Liestøl K, Holte H, Delabie J, Lind GE, Smeland EB (2014)
    A gene panel, including LRP12, is frequently hypermethylated in major types of B-cell lymphoma
    PLoS One, 9 (9), e104249
    DOI 10.1371/journal.pone.0104249, PubMed 25226156
  3. Danielsen SA, Lind GE, Kolberg M, Høland M, Bjerkehagen B, Sundby Hall K, van den Berg E, Mertens F, Smeland S, Picci P, Lothe RA (2014)
    Methylated RASSF1A in malignant peripheral nerve sheath tumors identifies neurofibromatosis type 1 patients with inferior prognosis
    Neuro Oncol, 17 (1), 63-9
    DOI 10.1093/neuonc/nou140, PubMed 25038505
  4. Sirnes S, Lind GE, Bruun J, Fykerud TA, Mesnil M, Lothe RA, Rivedal E, Kolberg M, Leithe E (2014)
    Connexins in colorectal cancer pathogenesis
    Int J Cancer, 137 (1), 1-11
    DOI 10.1002/ijc.28911, PubMed 24752574
  5. Sørlie T, Johnsen H, Vu P, Lind GE, Lothe R, Børresen-Dale AL (2014)
    Mutation screening of the TP53 gene by temporal temperature gel electrophoresis (TTGE)
    Methods Mol Biol, 1105, 315-24
    DOI 10.1007/978-1-62703-739-6_25, PubMed 24623239
  6. Vedeld HM, Andresen K, Eilertsen IA, Nesbakken A, Seruca R, Gladhaug IP, Thiis-Evensen E, Rognum TO, Boberg KM, Lind GE (2014)
    The novel colorectal cancer biomarkers CDO1, ZSCAN18 and ZNF331 are frequently methylated across gastrointestinal cancers
    Int J Cancer, 136 (4), 844-53
    DOI 10.1002/ijc.29039, PubMed 24948044
  7. Vedeld HM, Skotheim RI, Lothe RA, Lind GE (2014)
    The recently suggested intestinal cancer stem cell marker DCLK1 is an epigenetic biomarker for colorectal cancer
    Epigenetics, 9 (3), 346-50
    DOI 10.4161/epi.27582, PubMed 24384857

Publications 2013

  1. Ahmed D, Eide PW, Eilertsen IA, Danielsen SA, Eknæs M, Hektoen M, Lind GE, Lothe RA (2013)
    Epigenetic and genetic features of 24 colon cancer cell lines
    Oncogenesis, 2 (9), e71
    DOI 10.1038/oncsis.2013.35, PubMed 24042735
  2. Bethge N, Honne H, Hilden V, Trøen G, Eknæs M, Liestøl K, Holte H, Delabie J, Smeland EB, Lind GE (2013)
    Identification of highly methylated genes across various types of B-cell non-hodgkin lymphoma
    PLoS One, 8 (11), e79602
    DOI 10.1371/journal.pone.0079602, PubMed 24260260
  3. Bethge N, Lothe RA, Honne H, Andresen K, Trøen G, Eknæs M, Liestøl K, Holte H, Delabie J, Smeland EB, Lind GE (2013)
    Colorectal cancer DNA methylation marker panel validated with high performance in Non-Hodgkin lymphoma
    Epigenetics, 9 (3), 428-36
    DOI 10.4161/epi.27554, PubMed 24362313
  4. Håvik AB, Lind GE, Honne H, Meling TR, Scheie D, Hall KS, van den Berg E, Mertens F, Picci P, Lothe RA, Heim S, Brandal P (2013)
    Sequencing IDH1/2 glioma mutation hotspots in gliomas and malignant peripheral nerve sheath tumors
    Neuro Oncol, 16 (2), 320-2
    DOI 10.1093/neuonc/not230, PubMed 24311631
  5. Mesquita B, Lopes P, Rodrigues A, Pereira D, Afonso M, Leal C, Henrique R, Lind GE, Jerónimo C, Lothe RA, Teixeira MR (2013)
    Frequent copy number gains at 1q21 and 1q32 are associated with overexpression of the ETS transcription factors ETV3 and ELF3 in breast cancer irrespective of molecular subtypes
    Breast Cancer Res Treat, 138 (1), 37-45
    DOI 10.1007/s10549-013-2408-2, PubMed 23329352
  6. Nome T, Thomassen GO, Bruun J, Ahlquist T, Bakken AC, Hoff AM, Rognum T, Nesbakken A, Lorenz S, Sun J, Barros-Silva JD, Lind GE, Myklebost O, Teixeira MR, Meza-Zepeda LA, Lothe RA, Skotheim RI (2013)
    Common fusion transcripts identified in colorectal cancer cell lines by high-throughput RNA sequencing
    Transl Oncol, 6 (5), 546-53
    DOI 10.1593/tlo.13457, PubMed 24151535

Publications 2012

  1. Agesen TH, Sveen A, Merok MA, Lind GE, Nesbakken A, Skotheim RI, Lothe RA (2012)
    ColoGuideEx: a robust gene classifier specific for stage II colorectal cancer prognosis
    Gut, 61 (11), 1560-7
    DOI 10.1136/gutjnl-2011-301179, PubMed 22213796
  2. Ahmed D, Danielsen SA, Aagesen TH, Bretthauer M, Thiis-Evensen E, Hoff G, Rognum TO, Nesbakken A, Lothe RA, Lind GE (2012)
    A tissue-based comparative effectiveness analysis of biomarkers for early detection of colorectal tumors
    Clin Transl Gastroenterol, 3 (12), e27
    DOI 10.1038/ctg.2012.21, PubMed 23324654
  3. Andresen K, Boberg KM, Vedeld HM, Honne H, Hektoen M, Wadsworth CA, Clausen OP, Karlsen TH, Foss A, Mathisen O, Schrumpf E, Lothe RA, Lind GE (2012)
    Novel target genes and a valid biomarker panel identified for cholangiocarcinoma
    Epigenetics, 7 (11), 1249-57
    DOI 10.4161/epi.22191, PubMed 22983262
  4. Cekaite L, Rantala JK, Bruun J, Guriby M, Agesen TH, Danielsen SA, Lind GE, Nesbakken A, Kallioniemi O, Lothe RA, Skotheim RI (2012)
    MiR-9, -31, and -182 deregulation promote proliferation and tumor cell survival in colon cancer
    Neoplasia, 14 (9), 868-79
    DOI 10.1593/neo.121094, PubMed 23019418
  5. Håvik AB, Brandal P, Honne H, Dahlback HS, Scheie D, Hektoen M, Meling TR, Helseth E, Heim S, Lothe RA, Lind GE (2012)
    MGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCR
    J Transl Med, 10, 36
    DOI 10.1186/1479-5876-10-36, PubMed 22390413
  6. Lind GE, Ahmed D, Lothe RA (2012)
    Vimentin in upper gastrointestinal pathologies--letter
    Cancer Epidemiol Biomarkers Prev, 21 (10), 1889; author reply 1890
    DOI 10.1158/1055-9965.EPI-12-0894, PubMed 22929079
  7. Sveen A, Bakken AC, Ågesen TH, Lind GE, Nesbakken A, Nordgård O, Brackmann S, Rognum TO, Lothe RA, Skotheim RI (2012)
    The exon-level biomarker SLC39A14 has organ-confined cancer-specificity in colorectal cancer
    Int J Cancer, 131 (6), 1479-85
    DOI 10.1002/ijc.27399, PubMed 22173985
 
Page visits: 8102
Scroll to top